Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Evaxion veranstaltet F&E-Tag und stellt das breite Potenzial seiner AI-Immunology™-Plattform vor: https://upload.wikimedia.org/wikipedia/commons/thumb/3/32/GSK_logo_2022.svg/1024px-GSK_logo_2022.svg.png
Evaxion veranstaltet F&E-Tag und stellt das breite Potenzial seiner AI-Immunology™-Plattform vor
  • Die unternehmenseigene AI-Immunology™-Plattform bietet das Potenzial für eine neue Ära der Entdeckung, des Designs und der Entwicklung von Impfstoffen mithilfe fortschrittlicher KI- und
GlobeNewswire 
0 20.03.24
iTeos kündigt strategische Prioritäten für 2024 und voraussichtliche Meilensteine an: https://upload.wikimedia.org/wikipedia/commons/thumb/3/32/GSK_logo_2022.svg/1024px-GSK_logo_2022.svg.png
iTeos kündigt strategische Prioritäten für 2024 und voraussichtliche Meilensteine an

- Klinische Daten aus dem TIGIT-Programm werden für 2024 erwartet, darunter zwei Phase-II-Studien zur Bewertung von Belrestotug + Dostarlimab bei NSCLC und HNSCC in der Erstlinie

- Klinische

GlobeNewswire 
0 08.01.24
Blackford arbeitet mit Oxipit zusammen, um das Angebot an KI-Lösungen für das Thorax-Röntgen zu erweitern
Blackford arbeitet mit Oxipit zusammen, um das Angebot an KI-Lösungen für das Thorax-Röntgen zu erweitern

EDINBURGH, Schottland, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Blackford, der bahnbrechende Anbieter von strategischen KI-Plattformen und -Lösungen für die Radiologie, hat heute eine Partnerschaft mit

GlobeNewswire 
0 22.11.23
Novotech ernennt Dr. Judith Ng-Cashin zum Chief Medical Officer zur Ausweitung globaler medizinischer Dienstleistungen: https://upload.wikimedia.org/wikipedia/commons/thumb/3/32/GSK_logo_2022.svg/1024px-GSK_logo_2022.svg.png
Novotech ernennt Dr. Judith Ng-Cashin zum Chief Medical Officer zur Ausweitung globaler medizinischer Dienstleistungen

BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Novotech, das führende, auf den asiatisch-pazifischen Raum ausgerichtete Biotech-Auftragsforschungsinstitut mit globalen Umsetzungsmöglichkeiten, gab

GlobeNewswire 
0 04.10.23
Accumulus Synergy ernennt Jacques Mascaro zum Verwaltungsratsvorsitzenden
Accumulus Synergy ernennt Jacques Mascaro zum Verwaltungsratsvorsitzenden

BURLINGAME, Kalifornien, June 22, 2023 (GLOBE NEWSWIRE) -- Accumulus Synergy („Accumulus“), eine gemeinnützige Handelsvereinigung, die sich mit dem globalen Bedarf an digitaler Transformation im

GlobeNewswire 
0 22.06.23
Accumulus Synergy gibt Ernennung neuer Mitglieder des Führungsteams bekannt: https://upload.wikimedia.org/wikipedia/commons/thumb/3/32/GSK_logo_2022.svg/1024px-GSK_logo_2022.svg.png
Accumulus Synergy gibt Ernennung neuer Mitglieder des Führungsteams bekannt

BURLINGAME, Kalifornien, May 15, 2023 (GLOBE NEWSWIRE) -- Accumulus Synergy („Accumulus“), ein gemeinnütziger Wirtschaftsverband, der sich mit dem weltweiten Bedarf an digitaler Transformation im

GlobeNewswire 
0 15.05.23
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=a2e20e899e5ab994754dd16899a8a74c
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
eqs_en 
0 07.06.22
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma


GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed

BusinessWire_EN 
0 06.08.20
AstraZeneca: Kurs-Irrsinn nach Impfstoff-News
AstraZeneca: Kurs-Irrsinn nach Impfstoff-News

Papiere des britischen Pharmakonzerns AstraZeneca (WKN: 886455) verteuern sich heute Morgen um zeitweise +30% auf 120 Euro. Börsenlaien lassen sich von einem am Wochenende vermeldeten Impfstoff-Deal

sharedeals 
0 15.06.20
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer


GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)

BusinessWire_EN 
0 24.04.20
Eine neu veröffentlichte multizentrische RCT zeigt, dass Smith+Nephew PICO◊ sNPWT kanisterlose Unterdruck-Wundtherapie herkömmlicher tNPWT bei der Reduzierung von Wundfläche, -tiefe und -volumen bei DFU und UCV überlegen ist
Eine neu veröffentlichte multizentrische RCT zeigt, dass Smith+Nephew PICO◊ sNPWT kanisterlose Unterdruck-Wundtherapie herkömmlicher tNPWT bei der Reduzierung von Wundfläche, -tiefe und -volumen bei DFU und UCV überlegen ist


Smith+Nephew (LSE:SN, NYSE:SNN), das globale Medizintechnikunternehmen, freut sich, die Veröffentlichung von Ergebnissen aus einer neuen randomisierten kontrollierten klinischen Studie (RCT)

BusinessWire_DE 
0 23.01.20
Clinical trial demonstrated superior wound closure rates with PICO◊ compared to traditional NPWT in lower extremity ulcers1
Clinical trial demonstrated superior wound closure rates with PICO◊ compared to traditional NPWT in lower extremity ulcers1


Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single

BusinessWire_EN 
0 16.01.20
3 High-Yield Stocks Still Worth Buying
3 High-Yield Stocks Still Worth Buying
Who doesn't like free money? While they may be somewhat forgotten as the stock market hits seemingly one new high after another, high-yield dividend stocks play an important role in providing....
TheMotleyFool 
0 19.12.17
Is a Dividend Cut Coming From GlaxoSmithKline plc?
Is a Dividend Cut Coming From GlaxoSmithKline plc?
One of the attractions of investing in British drugmaker GlaxoSmithKline plc (NYSE: GSK) is its generous dividend yield, which lately has hovered at just a bit less than 6%. A yield that's so far....
TheMotleyFool 
0 02.12.17
Better Buy: GlaxoSmithKline plc vs. Pfizer
Better Buy: GlaxoSmithKline plc vs. Pfizer
Big drug companies can add an element of stability to investor portfolios. People get sick and need treatment whether the economy is booming or tanking. And big pharma tends to pay hefty....
TheMotleyFool 
0 30.11.17
Here's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
Here's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
Shares of U.K.-based Big Pharma giant GlaxoSmithKline (NYSE: GSK) tumbled during the month of October, according to data from S&P Global Market Intelligence, losing nearly $10 billion in....
TheMotleyFool 
0 08.11.17
3 International Stocks for Retirees
3 International Stocks for Retirees
Retirees these days are living longer than ever before. That means there's a need to not only sustain your income with dividends, but also to grow your nest egg by investing in high-quality....
TheMotleyFool 
0 07.11.17
3 High-Yield International Stocks
3 High-Yield International Stocks
Because of the generally more favorable corporate tax rates abroad, international stocks can, on occasion, offer enormous yields that are sustainable in the long term. The international investing....
TheMotleyFool 
0 30.10.17
Ionis Pharmaceuticals Tumbles on Biogen's Miss: Buy or Sell?
Ionis Pharmaceuticals Tumbles on Biogen's Miss: Buy or Sell?
Ionis Pharmaceuticals (NASDAQ: IONS) lost 11% of its market value after commercialization partner Biogen (NASDAQ: BIIB) reported third-quarter sales of its drug, Spinraza, that failed to match....
TheMotleyFool 
0 25.10.17
Why MannKind, Nutanix, and Smith & Nephew Jumped Today
Why MannKind, Nutanix, and Smith & Nephew Jumped Today
The stock market ticked up on Tuesday, with the Dow and other major benchmarks posting gains of 0.1% to 0.3%. Concerns about the fate of the tax reform proposal in Washington continued to have....
TheMotleyFool 
0 10.10.17
What's Behind AstraZeneca's September Rebound?
What's Behind AstraZeneca's September Rebound?
After a tough couple of months, British pharma giant AstraZeneca (NYSE: AZN) actually saw its shares rise by a healthy 12.5% last month, according to data from S&P Global Market Intelligence.....
TheMotleyFool 
0 08.10.17
Caveat Emptor When Buying High-Yield Drug Stocks
Caveat Emptor When Buying High-Yield Drug Stocks
Income investors seemingly have hundreds of stocks to choose from that currently pay a dividend. The telecom and utility sectors often generate some of the most robust payouts for investors, with....
TheMotleyFool 
0 26.09.17
12 Flu Season Facts You Need to Know
12 Flu Season Facts You Need to Know
Fall is officially here, and that usually means three things: pumpkin-spiced everything is back in style, our lush trees are about to become leafless sticks, and that sniffle and cough could be....
TheMotleyFool 
0 24.09.17
3 Things Amgen Inc.'s Management Just Said That You'll Want to Know
3 Things Amgen Inc.'s Management Just Said That You'll Want to Know
It's been a great 2017 for Amgen (NASDAQ: AMGN) shareholders so far. Amgen stock is up close to 30%. The company announced several positive developments from its pipeline. Still, though, some....
TheMotleyFool 
0 12.09.17
Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc
Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc
Big drugmaker. High dividend yield. Promising new products. All three apply to AbbVie Inc. (NYSE: ABBV). They also all apply to GlaxoSmithKline plc (NYSE: GSK). But while AbbVie stock has achieved....
TheMotleyFool 
0 08.09.17